Abstract
Background: 6-mercaptopurine usage is associated with myelotoxicity and increased risk in patients carrying metabolism-related genetic variations. This study aimed to determine the frequency of candidate genepolymorphisms and their association with 6-mercaptopurine intolerance. Methods: A total of41 patients on acute lymphoblastic leukaemia treatment were genotyped for TPMT andNUDT15 (rs116855232) alleles, and theirassociation with dose intensity wasanalyzed. Results: The defective TPMT*3C allele frequency was 9.8%. The median maintenance dose intensity for TPMT*1/*3C participants was considerably lower (47%) when compared withthe TPMT*1/*1 wild-type (77%), althoughnot statistically significant. Conclusion: This is the first pharmacogenetics study carried outin a black Zimbabwean leukemia patient cohort. The high defective TPMT*3C (9.8%) allele frequency points to the potential utility of pharmacogenetics testing for safe usage of 6-mercaptopurine in this population.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
